Related Experiment Video

Updated: Dec 8, 2025

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model
06:45

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model

Published on: February 7, 2022

3.8K

Beta-blocker therapy in heart transplant recipients: A review

Daniele Masarone1, Rossella Vastarella1, Enrico Melillo1

  • 1Heart Failure and Cardiac Rehabilitation Unit, Department of Cardiology, AORN dei Colli-Monaldi Hospital, Naples, Italy.

Clinical Transplantation
|September 17, 2020
PubMed

Insights

Beta-blockers are now recognized as beneficial for heart transplant recipients, effectively treating various arrhythmias and improving heart function. Their use is associated with reduced mortality in these patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Beta-blockers are crucial for cardiovascular diseases like heart failure and hypertension.
  • Historically contraindicated in heart transplant recipients due to concerns about cardiac output.
  • Recent evidence suggests potential benefits in the post-transplant setting.

Purpose of the Study:

  • To review the current evidence on beta-blocker use in cardiac transplant patients.
  • To highlight the practical considerations for prescribing beta-blockers post-transplantation.
  • To encourage the clinical application of beta-blockers in this population.

Main Methods:

  • Literature review of studies on beta-blocker efficacy and safety in heart transplant recipients.
  • Analysis of data regarding treatment of specific cardiovascular conditions post-transplant.
  • Examination of mortality data associated with beta-blocker use.

Main Results:

  • Beta-blockers are effective in managing sinus tachycardia, supraventricular and ventricular tachyarrhythmias.
  • These drugs show utility in treating left ventricular systolic dysfunction and arterial hypertension.
  • Evidence indicates a correlation between beta-blocker use and reduced mortality in heart transplant recipients.

Conclusions:

  • Beta-blockers are safe and effective for managing cardiovascular conditions in heart transplant patients.
  • The historical contraindication for beta-blockers in this population is no longer supported by current evidence.
  • This review advocates for the increased use of beta-blockers in clinical practice for post-transplant care.

Keywords:
arrhythmiasheart rateheart transplantβ-blockers

More Related Videos

Murine Cervical Heart Transplantation Model Using a Modified Cuff Technique10:32

Murine Cervical Heart Transplantation Model Using a Modified Cuff Technique

Published on: October 12, 2014

14.6K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.7K

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
616
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
732
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
205
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
124